Immunotherapy in Non-Small-Cell Lung Cancer Patients with Driver Alterations: A New Strategy?

For many years, researchers have been trying to develop the most effective ways to fight lung cancer, which is the cause of the largest number of cancer-related deaths among men and women worldwide. The most advanced treatments for nearly all non-small-cell lung cancer (NSCLC) types include immunoth...

Full description

Saved in:
Bibliographic Details
Published in:Cells (Basel, Switzerland) Switzerland), 2022-10, Vol.11 (20), p.3280
Main Authors: Krzyżanowska, Natalia, Krawczyk, Paweł, Wojas-Krawczyk, Kamila, Kucharczyk, Tomasz, Milanowski, Janusz
Format: Article
Language:English
Subjects:
Apoptosis
Cancer therapies
Care and treatment
Chemotherapy
Cytotoxicity
Epidermal growth factor
Genes
immune checkpoint inhibitor
Immune checkpoint inhibitors
Immunogenicity
Immunotherapy
Kinases
Ligands
Lung cancer
Lung cancer, Non-small cell
Lymphocytes
Methods
molecularly targeted therapy
Monoclonal antibodies
Mutation
Non-small cell lung carcinoma
non-small-cell lung cancer
oncogenic driver alteration
PD-1 protein
PD-L1 protein
Protein-tyrosine kinase
Proteins
Review
Small cell lung carcinoma
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:For many years, researchers have been trying to develop the most effective ways to fight lung cancer, which is the cause of the largest number of cancer-related deaths among men and women worldwide. The most advanced treatments for nearly all non-small-cell lung cancer (NSCLC) types include immunotherapy with immune checkpoint inhibitors (ICIs), mainly anti-programmed death 1/anti-programmed death ligand 1 monoclonal antibodies (anti-PD-1/PD-L1 mAbs) in monotherapy or in combination with other strategies. Despite significant advances, long survival is not achievable in most cases, so new solutions are constantly being sought. One of the questions raised by oncologists is the efficacy of ICIs in patients with molecular driver alterations, especially when the possibilities of using molecularly targeted therapies are exhausted (e.g., due to resistance to tyrosine kinase inhibitors). There are studies investigating this problem, but it is still poorly described. Among probable immunotherapy’ failures reasons, low immunogenicity of tumors with one driver mutation is listed. Nevertheless, in some cases, the therapy is efficient, and more research is required to establish the management of NSCLC patients with oncogenic driver abnormalities. The aim of this article is to review current discoveries in this matter.
ISSN:2073-4409
2073-4409
DOI:10.3390/cells11203280